Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas

Cancer Discovery

Volumn 5, Issue 10, 2015, Pages 1040-1048

  Zill, Oliver A ^a,b,c   Greene, Claire ^a,b   Sebisanovic, Dragan ^c   Siew, Lai Mun ^c   Leng, Jim ^a,b   Vu, Mary ^d   Hendifar, Andrew E ^e   Wang, Zhen ^b   Atreya, Chloe E ^a,b   Kelley, Robin K ^a,b   Van Loon, Katherine ^a,b   Ko, Andrew H ^a,b   Tempero, Margaret A ^a,b   Bivona, Trever G ^a,b   Munster, Pamela N ^a,b   Talasaz, Amirali ^c   Collisson, Eric A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Revolution Medicines   (United States)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CELL FREE DNA; DNA; F BOX PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PROTEIN P53; SMAD4 PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; BLOOD ANALYSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MUTATION; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; PANCREAS CARCINOMA; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; BILE DUCT NEOPLASMS; BLOOD; CANCER STAGING; CARCINOMA; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION RATE; PANCREATIC NEOPLASMS; PROCEDURES; PROGNOSIS; REPRODUCIBILITY;

BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CARCINOMA; DISEASE PROGRESSION; DNA, NEOPLASM; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; MUTATION RATE; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84943303014     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0274     Document Type: Article

References (30)

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014;371:2140-1.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60:861-8.
5. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491:399-405.
6. Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. Qpure: a tool to estimate tumor cellularity from genome-wide singlenucleotide polymorphism profiles. PLoS One 2012;7:e45835.
7. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 2008;321:1801-6.
8. Tempero MA, Malafa MP, Behrman SW, Benson AB, 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 2014;12:1083-93.
9. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-501.
10. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383.
11. Loaiza-Bonilla A, Clayton E, Furth E, O’Hara M, Morrissette J. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience 2014;8:479.
12. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, et al. HER2/ neu-directed therapy for biliary tract cancer. J Hematol Oncol 2015;8:58.
13. Benson AB, 3rd, D’Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, et al. Hepatobiliary cancers, version 2.2014. J Nat Compr Cancer Netw 2014;12:1152-82.
14. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014;19:235-42.
15. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
16. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
17. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Sig 2013;6:pl1.
18. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 2004;304:1497-500.
19. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
20. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
21. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
22. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Agerelated mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:1472-8.
23. Benson AB, 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Nat Compr Cancer Net 2009;7:350-91.
24. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
25. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015;9:783-90.
26. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating- free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
27. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-84.
28. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012;7:115-21.
29. Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, et al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst 2014;106.
30. Altman DG, Bland JM. Diagnostic tests. 1: sensitivity and specificity. BMJ 1994;308:1552.